SOSUA BAY, Dominican Republic, Sept. 20, 2010 (GLOBE NEWSWIRE) -- Proton Laboratories, Inc. (Pink Sheets:PLBI - News) CEO, Armando Casciati, announced today that the clean lab modular system has been released from customs and delivered to the laboratory site across the street from the clinic in a standalone facility. "We expect the lab to be installed and the remaining two pieces of equipment to be delivered by the end of October," stated Mr. Casciati. Mr. Casciati went on to say that "we are taking every precaution to construct this laboratory to the standards needed to safeguard the process of stem cell regeneration and with the supervision of Dr. Lee, we are confident that it will be done properly. Once a patient's fatty tissue stem cells are removed and analyzed, the lab will be the key factor in the regeneration of new stem cells from clients and therefore must be processed in a very clean, secure environment with detailed record keeping and culture identification. The lab will also be the key in new research and development projects that may be presented.
About Proton Laboratories, Inc. and its wholly owned subsidiary RegenoBody S.A:
RegenoBody S.A., a wholly owned subsidiary of Proton Laboratories, Inc., brings the benefits of bioscience to patients who have been diagnosed with chronic debilitating diseases, offering viable, efficient therapeutic options with special Stem Cell Therapies utilizing the most effective cell regeneration techniques. Therapies are tailored for each individual, based upon their specific needs. Cells are obtained by the most modern technologic methods. The transplant physicians and stem cell laboratory scientists, associated with RNL Bio have been regarded as some of the best in the world. Stem cells derived from Autologous (Stem cells taken from your own body) and Allogeneic (Stem cells from a source other than your own) are used depending on the particular condition that needs to be treated. Treatments will be delivered by an experienced team of International and U.S. Board Certified Physicians who are guided by strict protocols ensuring excellence in medical care.
About RNL Bio Company LTD:
RNL Bio is a premier biopharmaceutical company focused on development and commercialization of adult stem cell therapeutics and dog cloning technology. Headquartered in Seoul with state-of-the-art GMP facility, RNL is publicly traded company on the Korea Exchange (Code 003190) and strives to become a global leader across the biomedical industry.
FORWARD-LOOKING STATEMENT:
This report contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may," "future," "plan" or "planned," "will" or "should," "expected," "anticipates," "draft," "eventually" or "projected." You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this report are made as of the date hereof and the company undertakes no obligation to update such statements.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment